Literature DB >> 19054146

Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma.

Shiro Miyayama1, Takeshi Mitsui, Yoh Zen, Yoshiko Sudo, Masashi Yamashiro, Miho Okuda, Yuichi Yoshie, Taku Sanada, Kazuo Notsumata, Nobuyoshi Tanaka, Osamu Matsui.   

Abstract

AIM: To evaluate the histopathologic findings in the surgical specimen of hepatocelluar carcinoma after transcatheter arterial chemoembolization (TACE) at the most distal portion of the sub-subsegmental artery of the liver (ultraselective TACE).
METHODS: Histolopathologic findings from nine tumors with a mean diameter of 3.1 cm +/- 1.7 from patients who underwent hepatectomy after ultraselective TACE were evaluated, especially with regard to the relationship between peritumoral liver parenchymal necrosis and portal vein visualization during TACE. Portal vein visualization was classified into three grades by a spot digital radiograph obtained just after TACE: 0, no obvious portal vein visualization; 1, visualization of the portal vein adjacent to the tumor; and 2, visualization in the whole embolized area or extending into the surrounding non-embolized areas. Unenhanced computed tomography (CT) was obtained 1 week later and surgical resection was performed 37 +/- 6.3 days after ultraselective TACE.
RESULTS: Portal vein visualization during TACE was classed as grade 1 in 5 tumors and grade 2 in 4. Histopathologically, complete tumor necrosis was observed in 7 tumors (77.8%). In 2 tumors (1 of grade 1, the other grade 2), a small viable portion or viable daughter nodule was seen. Macroscopic parenchymal necrosis adjacent to the tumor was observed in all 4 grade 2 tumors including gas-containing areas on CT obtained 1 week after TACE.
CONCLUSIONS: Ultraselective TACE induces not only complete tumor necrosis but also peritumoral parenchymal necrosis, similar to that after radiofrequency ablation, when the portal veins are markedly visualized during the TACE procedure.

Entities:  

Year:  2008        PMID: 19054146     DOI: 10.1111/j.1872-034X.2008.00465.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  13 in total

1.  Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?

Authors:  Koichiro Yamakado; Shiro Miyayama; Shozo Hirota; Kimiyoshi Mizunuma; Kenji Nakamura; Yoshitaka Inaba; Akihiro Maeda; Kunihiro Matsuo; Norifumi Nishida; Takeshi Aramaki; Hiroshi Anai; Shinichi Koura; Shigeo Oikawa; Ken Watanabe; Taku Yasumoto; Kinya Furuichi; Masato Yamaguchi
Journal:  Jpn J Radiol       Date:  2012-05-30       Impact factor: 2.374

2.  Ultraselective transcatheter infusion of epirubicin in water-in-oil-in-water emulsion for small hepatocellular carcinoma.

Authors:  I Ikushima; S Higashi; A Ishii; K Seguchi; Y Iryo; Y Yamashita
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

3.  Automatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility.

Authors:  Zhijun Wang; Eberhard Hansis; Rongxin Chen; Rafael Duran; Julius Chapiro; Yun Robert Sheu; Hicham Kobeiter; Michael Grass; Jean-François Geschwind; MingDe Lin
Journal:  Minim Invasive Ther Allied Technol       Date:  2016-02-29       Impact factor: 2.442

Review 4.  Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

Authors:  Norihiro Imai; Masatoshi Ishigami; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Yoshiki Hirooka; Hidemi Goto
Journal:  World J Hepatol       Date:  2014-12-27

5.  Pseudolesion of the liver observed on gadoxetate disodium-enhanced magnetic resonance imaging obtained shortly after transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Yoshinobu Shinagawa; Keiko Sakamoto; Ritsuko Fujimitsu; Mikiko Ida; Hiroshi Urakawa; Shin-Ichi Kora; Hideyuki Higashihara; Kouichi Takano; Kengo Yoshimitsu
Journal:  Jpn J Radiol       Date:  2010-07-27       Impact factor: 2.374

6.  Efficacy of Superselective Conventional Transarterial Chemoembolization Using Guidance Software for Hepatocellular Carcinoma within Three Lesions Smaller Than 3 cm.

Authors:  Shiro Miyayama; Masashi Yamashiro; Rie Ikeda; Junichi Matsumoto; Kiyotaka Takeuchi; Naoko Sakuragawa; Teruyuki Ueda; Taku Sanada; Kazuo Notsumata; Takuro Terada
Journal:  Cancers (Basel)       Date:  2021-12-19       Impact factor: 6.639

Review 7.  Ultraselective conventional transarterial chemoembolization: When and how?

Authors:  Shiro Miyayama
Journal:  Clin Mol Hepatol       Date:  2019-04-26

Review 8.  Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma.

Authors:  Charlotte Ebeling Barbier; Femke Heindryckx; Hans Lennernäs
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

9.  Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma.

Authors:  Joonho Jeong; Jung Gu Park; Kwang Ill Seo; Ji Hyun Ahn; Jae Chun Park; Byung Cheol Yun; Sang Uk Lee; Jin Wook Lee; Jong Hyouk Yun
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.889

10.  The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas.

Authors:  Tae Won Choi; Hyo-Cheol Kim; Jeong-Hoon Lee; Su Jong Yu; Beomsik Kang; Saebeom Hur; Myungsu Lee; Hwan Jun Jae; Jin Wook Chung
Journal:  Korean J Radiol       Date:  2015-10-26       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.